The company's Proteostasis Regulators are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. Proteostasis Therapeutics is committed to discovering and developing novel therapeutics to treat cystic fibrosis through theratyping, and all of its revenue is collaboration or license revenue earned from activities in the United States.